Trial Profile
Effects on cardiac, renal, and vascular endothelial markers after switching to topiroxostat from febuxostat treatment among IGT patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Topiroxostat (Primary)
- Indications Hyperuricaemia
- Focus Adverse reactions; Pharmacodynamics
- 01 Jul 2017 Status changed from active, no longer recruiting to completed.
- 30 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2015 New trial record